Navigation Links
2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma, a German biopharmaceutical company specialized in targeted therapies for malignant tumors, today announced, that data from the Phase IIb-study with AP 12009 in high-grade glioma will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the open-label, randomized dose-finding Phase IIb-trial adult patients with recurrent or refractory high-grade glioma were treated either with one of two doses of the TGF-beta2 inhibitor AP 12009 - applied by convection-enhanced delivery - or chemotherapy (temozolomide or PCV) as a control. Survival data in the subgroup of anaplastic astrocytoma patients suggest superiority of AP 12009 over chemotherapeutic treatment.

Median overall survival has not yet been reached in both AP 12009 dose groups in contrast to 91 weeks in the chemotherapy treatment group. Overall response rates demonstrate a benefit of AP 12009 over chemotherapy. The duration of long-term tumor responses until now exceeds the active treatment period by far.

“The significance of our clinical research findings is reflected by the fact, that the Scientific Program Committee has chosen the data for poster discussion among many high quality abstracts”, says the coordinating investigator of the study, Prof. Ulrich Bogdahn, MD, University of Regensburg, Germany. Data from the Phase IIb-study on efficacy and safety in anaplastic astrocytoma patients will be discussed by Albert J. Wong, MD on Sunday June 3rd 2007 in the session “Central Nervous System Tumors” from 11:15 a.m. to 11:30 a.m. in room S100a on Level 1 of McCormick Place South Building.

Prof. Bogdahn will be available for further discussion at the poster entitled “A Phase IIb actively controlled study with the TGF-beta2 inhibito
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
5. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
6. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
8. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
9. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting

Post Your Comments:
(Date:11/25/2009)..., LOVELAND,Colo.,Nov.25/PRNewswire-FirstCall/--...f advanceddiagnosticandspecialtyproductstothevete...agnosticsCorporationforthesupplyofbloodgasproducts..., (Logo: http://www.newscom.com/cgi-bin/prnh/200...passionforinnovatinginthefieldofadvancedpoint-of-c...
(Date:11/25/2009)..., PRINCETON,N.J.,Nov.25/PRNewswire-FirstCall/--...aceuticalcompanycommittedtodiscovering,developinga...reportedfinancialresultsforthefiscalyearendedSepte...illionincash,cashequivalentsandshortterminvestment...RG7128 ,, Phase2bTrial ,, InlateNovembe...
(Date:11/25/2009)..., CHICAGOandSTAFA,Switzerland,Nov.25/PRNewswire...rofinnovativehearingsolutions,presentedtheseconded...nthespecialneedsoftheolderpopulation.Theconference...omaroundtheworldandmorethan250clinicianswhoworkeve...ytoshareexperiencesanddiscussthelatestresearchandt...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3FDA Acts to Protect Public Health from Electronic Cigarettes 52470 1FDA Acts to Protect Public Health from Electronic Cigarettes 52470 2FDA Acts to Protect Public Health from Electronic Cigarettes 52470 3Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 1Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 2Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 1Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 4Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 5Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 6Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 7Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 8
...rship Strengthened with Clinical Trials S...PANY, N.J. and ATLANTA, Sept. 6 Image Solutions,I...quire Zurich,Biostatistics, Inc. (ZBI). With the L...gulatory submissions, the acquisition further stre...Consortium (CDISC) capabilities,the FDA-supported ...
...tor to Enter Registration Trials, HAYWARD, Calif.... KOSN ) today announced that it has successfully,... Drug Administration,(FDA) on the design of its TI...s Hsp90 inhibitor tanespimycin as a treatment for ...Special Protocol Assessment (SPA),process, Kosan a...
Other Medicine Technology:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:11/27/2009)...,, KIBBUTZSHAMIR,Israel,Nov.27/PRNewswire-First...Shamir" ),aleadingproviderofinnovativeproductsandt...hatitsboardofdirectorshaddeclaredadividenddistribu...yNIS37.62millionbasedontheNovember25,2009represent...ximatelyNIS2.3basedontheNovember25,2009representat...
(Date:11/27/2009)... Voyant Health™ annou...higan) has licensed its TraumaCad Enterprise ortho... workflow solution. , (PR...ounced today that Spectrum Health (Grand Rapids, M...hopedic templating solution and its TraumaCad Exte...
(Date:11/26/2009)...,, PRINCETON,N.J.,Nov.27/PRNewswire/--Thediabet...henext25yearsandannualmedicalspendingonthediseasei...accordingtoastudypublishedintheDecemberissueof Dia...ram(NCDP),aprogramofNovoNordisk,commissionedtheana...rdingtotheforecast,thenumberofAmericanslivingwithd...
(Date:11/26/2009)... No more letters from the N...personalized text messages from Santa , ...ort to increase operational efficiencies at the No...to help keep children all over the globe informed ...lves in Santa’s research department have ide...
(Date:11/25/2009)...,, EDINA,Minn.,Nov.25/PRNewswire-USNewswire/--W...tist.Butachiropractorcanalsogivepatientsthehelpthe...hiswhereyourjaw(mandible)contacts/connectswithyour...sociatedwithTMJdysfunctionarepainwithchewing,click...edfromTMJdysfunctionincluding:headaches,fatigue,sl...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...women demand epidurals during delivery even if not...atest demand of midwives through the experts at Ro... would help stem the// growing number of women ask...pidural though relieves pain during child birth, t...
...cer has acquired a new twist in its sordid journey...d upon “Stem Cells” and their involvement in the d...ation to say that stem cells may hold clues for la...his is probably the reason why a tumor resurfaces ...
... Vado Diomande, a childhood dancer, from the tende...“Mask Dance” has suffered a setback to his health....ts, as it was thought to be. // On Thursday,...etching the animal skins on drums for the purpose ...
...en are too busy building careers, and raking in th...babies that result in delayed motherhood, reveals ...very boring read, a loss of 92,000 babies each yea... of infertility. But Women seem to be stuck up on ...
...ew study appearing in the February 22 issue of the... no significant differences in the effectiveness o... or paclitaxel. Drug-releasing stents are known to...r the outcome of procedures like angioplasty, when...
...thwestern Memorial Hospital along with Northwester...ting a Phase II clinical trial to determine if ava...drug also known as bevacizumab is an anti-angiogen...adiation therapy and chemotherapy can reduce local...
Other Medicine News:Health News:Avastin under trial to test efficacy for pancreatic tumours! 2
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: